Skip to main content

WTW acquires Redefind to strengthen digital asset protection offering

LONDON, June 02, 2026 (GLOBE NEWSWIRE) — WTW (NASDAQ:WTW), a leading global advisory, broking and solutions company has today announced its acquisition of Redefind, an end-to-end web-based platform, designed to facilitate access to insurance products for crypto and digital assets. This investment reflects WTW’s long-term strategy to expand into next-generation protection solutions for clients exposed to digital finance, crypto ecosystems and tokenised asset environments. The proposition launches as a non-custodial, cost-of-recovery insurance solution, intended to support digital asset owners in the event of theft or loss. Coverage is designed to support expenses associated with forensic investigation, asset tracing, and legal recovery of stolen digital assets. As part of the acquisition, Redefind’s founders, Richard Daws and Connor...

Continue reading

Ingredion acquires Benicaros® — a prebiotic fiber that supports immune health at extremely low daily dosage/intake

Unique upcycled prebiotic with clinically proven immune health benefits extends Ingredion’s leading global portfolio of clean-label, functionally beneficial ingredients WESTCHESTER, Ill., June 02, 2026 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions for the food, beverage and industrial markets, announced the acquisition of Benicaros®, a patented, prebiotic fiber made from upcycled carrot pomace clinically shown to support immune health. “As we expand our functional ingredients offering, Benicaros’ versatility and health benefits makes it a perfect fit for our portfolio,” said Nate Yates, Ingredion’s vice president & general manager of sugar reduction and fiber fortification. “This highly differentiated prebiotic carrot fiber addresses the limitations of traditional...

Continue reading

Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096

FDA considered the planned HER-096 Phase 2a study design appropriate Study design finalized; approximately 100 patients to be enrolled More than 50% of Phase 2 funding secured or identifiedEspoo, Finland, 2 June 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today provides an update on preparations for the Phase 2a proof-of-concept efficacy study of HER-096, its lead candidate for the treatment of Parkinson’s disease, ahead of its webcast being hosted later today at 13.00 EEST (12:00 CEST). Herantis recently completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned clinical development of HER-096. The FDA raised no concerns regarding the Company’s chemistry, manufacturing and...

Continue reading

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals  Two oral presentations of novel, investigational ACTH receptor antagonist atumelnant include full Phase 2 study results in congenital adrenal hyperplasia and data from additional patients in the Phase 1b/2a ACTH-dependent Cushing’s syndrome study SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that data from six abstracts, including oral presentations featuring PALSONIFY™ (paltusotine) and investigational candidate atumelnant, will be presented at the Endocrine Society’s Annual Meeting, ENDO 2026, June 13-16, 2026, in Chicago, IL. “At ENDO 2026, new data will be presented which...

Continue reading

WeRide, Uber and AVOMO Bring Robotaxis to Madrid

First joint market entry in Europe, with public operations expected in later this year via the Uber app In partnership with the Madrid Regional GovernmentMADRID, June 02, 2026 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, and Uber Technologies, Inc. (NYSE: UBER) today announced plans to launch Spain’s first commercial Robotaxi pilot in the Region of Madrid, marking the companies’ first joint entry into the European market. The service is expected to begin operations later this year, in collaboration with Madrid’s Regional Government (Comunidad de Madrid), with rides available via the Uber app. The parties expect the fleet to scale progressively and will initially include trained vehicle operators, with WeRide, AVOMO and Uber committed to adding hundreds of Robotaxis as...

Continue reading

Meridian Holdings Subsidiary Expanse Studios Signs Content Distribution Agreement with Flutter Subsidiary MaxBet for Serbian Market

Integration Strengthens the Company’s Position in one of Southeast Europe’s Largest iGaming MarketsExpanse Studios x MaxbetExpanse Studios x MaxbetLAS VEGAS, June 02, 2026 (GLOBE NEWSWIRE) — Meridian Holdings Inc. (NASDAQ: MRDN) (“Meridian” or the “Company”), a global operator and technology provider in online sports betting and iGaming markets, today announced that the Company’s subsidiary, Expanse Studios, a leading B2B iGaming content provider, has signed a strategic distribution agreement with MaxBet, one of Serbia’s leading omni-channel gaming operators and a subsidiary of Flutter Entertainment plc (NYSE: FLUT; LSE: FLTR). The agreement will enable Expanse to further expand the reach of its proprietary gaming portfolio across the Serbian market By integrating with MaxBet’s established infrastructure, Expanse Studios...

Continue reading

Reducing management fee cap by 20% over two years to 1.00% of NAV

ICG Enterprise Trust plc 2 June 2026 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (“UK MAR”). Reducing management fee cap by 20% over two years to 1.00% of NAV ICG Enterprise Trust plc (the “Company”) announces that it has agreed a 20% reduction in the management fee cap payable to ICG Alternative Investment Limited (the “Manager”), a subsidiary of ICG plc, which will be implemented in two stages:       1)   From 1 February 2027 the management fee cap will be reduced to 1.125% of NAV; and       2)   From 1 February 2028 the cap will be reduced to 1.00% of NAV. Jane Tufnell, Chair of the Company, commented:“I am pleased that ICG Enterprise Trust plc is announcing a...

Continue reading

Form 8.3 – [ANIMALCARE GROUP PLC – 01 06 2026] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ANIMALCARE GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 01 06 2026] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

UP Fintech Holding Limited Reports Unaudited First Quarter 2026 Financial Results

SINGAPORE, June 02, 2026 (GLOBE NEWSWIRE) — UP Fintech Holding Limited (NASDAQ: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced its unaudited financial results for the first quarter ended March 31, 2026. Mr. Wu Tianhua, Chairman and CEO of UP Fintech stated: “In the first quarter, we continued to expand our user base and client assets, while further optimizing our comprehensive product offerings. Supported by these solid fundamentals, both our topline and operating performance have achieved notable year-over-year growth. Our total revenue for the first quarter reached US$154.9 million, representing a 26.3% increase year over year. Net loss and non-GAAP net loss attributable to UP Fintech for the quarter were $26.9 million and $23.8 million, versus net income of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.